Resignation of Auditor

RNS Number : 5200I

Nuformix PLC

05 December 2022

 

5 December 2022

Nuformix plc

("Nuformix" or the "Company")

Resignation of Auditor

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the Company.  Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys Henry to send a statement of the reasons for ceasing to hold office.  They have stated that in accordance with Section 519 of the Act, they are ceasing to hold office due to the following reason:

"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has taken the decision not to register as an auditor eligible to undertake Public Interest Entity audits."

There are no circumstances connected with Jeffreys Henry ceasing to hold office as auditor which they consider should be brought to the attention of the Company's members or creditors.  As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.

The appointment of a new auditor will be announced in due course following the completion of a tender process.

Enquiries:

Nuformix plc
Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

END

 

 

APPFLFSTFLLSIIF